Univariable analyses examining response, toxicities, PFS and OS in association with body composition measures (n=287)
| Response | OR | 95% CI | P value |
| SMI (sarcopenic vs non-sarcopenic) | 0.89 | 0.56 to 1.42 | 0.62 |
| SMD (high vs low) | 1.15 | 0.72 to 1.83 | 0.56 |
| SMG (high vs low) | 1.24 | 0.77 to 1.99 | 0.37 |
| TATI (medium vs low) | 1.16 | 0.66 to 2.05 | 0.61 |
| TATI (high vs low) | 0.79 | 0.44 to 1.40 | 0.43 |
| Sarcopenic obese (yes vs no) | 0.60 | 0.30 to 1.20 | 0.15 |
| Toxicities | OR | 95% CI | P value |
| SMI (sarcopenic vs non-sarcopenic) | 0.90 | 0.56 to 1.44 | 0.67 |
| SMD (high vs low) | 0.78 | 0.49 to 1.25 | 0.30 |
| SMG (high vs low) | 0.84 | 0.52 to 1.35 | 0.47 |
| TATI (medium vs low) | 0.85 | 0.478 to 1.50 | 0.57 |
| TATI (high vs low) | 0.74 | 0.42 to 1.32 | 0.32 |
| Sarcopenic obese (yes vs no) | 0.62 | 0.31 to 1.23 | 0.17 |
| PFS | HR | 95% CI | P value |
| SMI (sarcopenic vs non-sarcopenic) | 1.15 | 0.87 to 1.51 | 0.33 |
| SMD (high vs low) | 0.97 | 0.74 to 1.28 | 0.85 |
| SMG (high vs low) | 0.90 | 0.68 to 1.19 | 0.47 |
| TATI (medium vs low) | 0.82 | 0.58 to 1.16 | 0.26 |
| TATI (high vs low) | 1.11 | 0.80 to 1.55 | 0.51 |
| Sarcopenic obese (yes vs no) | 1.47 | 1.02 to 2.12 | 0.037 |
| OS | HR | 95% CI | P value |
| SMI (sarcopenic vs non-sarcopenic) | 1.28 | 0.93 to 1.77 | 0.135 |
| SMD (high vs low) | 0.76 | 0.55 to 1.04 | 0.09 |
| SMG (high vs low) | 0.78 | 0.57 to 1.08 | 0.14 |
| TATI (medium vs low) | 0.83 | 0.56 to 1.24 | 0.37 |
| TATI (high vs low) | 1.01 | 0.59 to 1.48 | 0.97 |
| Sarcopenic obese (yes vs no) | 1.34 | 0.88 to 2.05 | 0.17 |
P values ≦0.05 are displayed in bold.
OS, overall survival; PFS, progression-free survival; SMD, skeletal muscle density; SMG, skeletal muscle gauge; SMI, skeletal muscle index; TATI, total adipose tissue index.